Stocks · News reference

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

Aug 6, 2026, 7:52 PMBenzinga Newsdesk

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 27, 2026, 2:01 PMBenzinga Newsdesk
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Read original at benzinga
MIRM
BenzingaAug 6, 2026, 5:40 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.
Read original at benzinga
MIRM
BenzingaAug 6, 2026, 1:00 PMBenzinga Newsdesk
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
Read original at benzinga
MIRM